Dow soars more than 700 points, after favorable, early results for coronavirus vaccine candidate

U.S. stocks soared at the start of Monday trading after drugmaker Moderna announced positive, early results from its first human trial of its experimental Covid-19 vaccine.

On Friday, the Dow rose 61 points, or less than 0.3%, to 23,685.42, while the S&P 500 rose 11.20 points, or 0.4%, higher to end the session at 2,863.70. The Nasdaq Composite Index closed at 9,014.56 after gaining 70.84 points, or 0.8%. “These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25” micrograms, Moderna chief medical officer Dr. Tal Zaks said in a news release. The next step is a Phase 2 trial, which has been approved to move forward by the Food and Drug Administration. The trial was done in partnership with the National Institute of Allergy and Infectious Diseases.

That said, the monetary-policy maker struck a cautiously sanguine tone about the likelihood for a rebound for an economy that has shown signs of the extreme toll taken on it by measures put in place to limit the spread of the pathogen. Meanwhile, data on Monday showed Japan’s economy, shrank by an annualized 3.4% in the three months ended March 31 after a 7.3% contraction in the previous quarter, meeting the commonly accepted definition for a recession.

Rising cases in the U.S., however, where there are more than a third of the 4.7 million world-wide infections, has underpinned fitful trade in assets considered risky. Deaths in the U.S. rose above 89,500, more than a quarter of the more than 315,000 world-wide, according to figures from Johns Hopkins.

LMFAO nothing is real right now no guidance massive unemployment more to come fake liquidity earnings terrible etc etc etc .. I digress Reality is Hopium is an addicts dream right now

Law Law Latest News, Law Law Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Moderna's stock soars on positive early-stage data for its coronavirus vaccine candidateShares of Moderna Inc. jumped 25.1% in premarket trading on Monday after the biotechnology company announced positive results from a Phase 1 clinical trial for its experimental mRNA coronavirus vaccine. The trial was done in partnership with the National Institute of Allergy and Infectious Diseases. Within 43 days and after two doses, the participants taking one of two dosing levels of the vaccine candidate reported the same or higher level of antibodies as in blood samples gathered by patients who have recovered from COVID-19, the company said. There were four adverse events during the trial, including one participant who reported a severe skin reaction where the investigational vaccine was administered. "These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25" micrograms, Moderna chief medical officer Dr. Tal Zaks said in a news release. The next step is a Phase 2 trial, which has been approved to move forward by the Food and Drug Administration. It will focus on two dosing levels (50 microgram and 100 microgram). The early-stage trial had a third dosing level, 250 micrograms. Moderna's vaccine candidate is widely viewed as a frontrunner in the effort to develop the first vaccine for the virus. The preclinical company said earlier this month that the Phase 2 trial will begin "shortly," and on Monday it said it expects a Phase 3 trial to begin in July, if the vaccine is successful in the mid-stage trial. Moderna's stock has soared 240.9% year-to-date. The S&P 500 , in comparison, is down 11.3%. Classic PR stunt... I wonder how many of these pharma companies will mislead us.
Source: MarketWatch - 🏆 3. / 97 Read more »